Immunic, Inc. to Report Second Quarter 2020 Financial Results and Provide Corporate Update

30.07.20 22:20

DGAP-News: Immunic, Inc. / Key word(s): Miscellaneous
Immunic, Inc. to Report Second Quarter 2020 Financial Results and Provide Corporate Update

30.07.2020 / 22:15
The issuer is solely responsible for the content of this announcement.

Immunic, Inc. to Report Second Quarter 2020 Financial Results and Provide Corporate Update

NEW YORK, July 30, 2020 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company focused on developing best-in-class, oral therapies for the treatment of chronic inflammatory and autoimmune diseases, today announced that it will report financial results for the second quarter ended June 30, 2020, and provide a corporate update on Monday, August 3, 2020 before the opening of the U.S. financial markets.

Immunic will host a public conference call and webcast at 8:30 a.m. Eastern Time on Monday, August 3, 2020. To participate in the conference call, dial 1-877-870-4263 (USA) or 1-412-317-0790 (International) and ask to be joined into the Immunic, Inc. call. A live, listen-only webcast of the conference call can be accessed at or on the "Events and Presentations" section of Immunic's website at

An archived replay of conference call and webcast will be available approximately one hour after the completion for one year on Immunic's website at:

About Immunic, Inc.
Immunic, Inc. (Nasdaq: IMUX) is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's disease, and psoriasis. The company is developing three small molecule products: lead development program, IMU-838, is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH and exhibits a host-based antiviral effect; IMU-935 is an inverse agonist of RORγt; and IMU-856 targets the restoration of the intestinal barrier function. IMU-838 is in phase 2 clinical development for COVID-19, relapsing-remitting multiple sclerosis and ulcerative colitis, with an additional phase 2 trial considered in Crohn's disease. An investigator-sponsored proof-of-concept clinical trial for IMU-838 in primary sclerosing cholangitis is ongoing at the Mayo Clinic. For further information, please visit:

Cautionary Statement Regarding Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Immunic's three development programs and the targeted diseases; the potential for IMU-838, IMU-935 and IMU-856 to safely and effectively target diseases; preclinical data for IMU-856; the timing of future clinical trials; the nature, strategy and focus of the company; and the development and commercial potential of any product candidates of the company. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, the COVID-19 pandemic, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient resources to meet business objectives and operational requirements, the fact that the results of earlier studies and trials may not be predictive of future clinical trial results, the protection and market exclusivity provided by Immunic's intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned "Risk Factors," in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 16, 2020, the company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, filed with the SEC on May 8, 2020, and in the company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at or Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.

Contact Information

Immunic, Inc.
Jessica Breu
Head of Investor Relations and Communications
+49 89 2080 477 09


Rx Communications Group
Melody Carey

30.07.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at

1106797  30.07.2020 



Breaking News

Weitere Meldungen
31.07 Directors' Dealings: Baader B.
31.07 132 Berufseinsteiger starten.
31.07 DGAP-NVR: Fresenius SE &.
31.07 Veränderungen im Vorstand .
31.07 Stimmrechtsanteile: MorphoSy.
31.07 Baumot Group veröffentlicht .
31.07 Benjamin Schmid ab August.
31.07 Hardman & Co Research: Q.
31.07 KERAMUNDO: Handelsblatt: .
31.07 OTI Greentech AG: OTI Gre.
31.07 CR Capital Real Estate AG.
31.07 Directors' Dealings: Krones A.
31.07 Directors' Dealings: Vonovia .
31.07 Mynaric stellt alle Geschäfts.
31.07 Stimmrechtsanteile: Epigenom.
31.07 Stimmrechtsanteile: Bertrandt.
31.07 Zulassungsfolgepflichten: Fre.
31.07 MAGNIT PJSC: Magnit anno.
31.07 Muehlhan AG: Muehlhan AG.
31.07 PJSC RusHydro: Notice of r.
31.07 Stimmrechtsanteile: ENCAVI.
31.07 Eve Sleep plc: Holding in Co.
31.07 RIB Software SE kann auf .
31.07 Befesa S.A.: Befesa erzielt.
31.07 MBH Corporation plc gibt vie.
31.07 Nemetschek SE: Stabile Ums.
31.07 AURELIUS Tochter Office D.
31.07 Tern PLC: Total Voting Rig.
30.07 Immunic, Inc. to Report Sec.
30.07 Einladung zur Telefonkonfere.

Welche Social Networks nutzen Sie meistens?
Linked in

Stimmen: 85527 , Ergebnis

Status: nicht eingeloggt

Registrieren | Passwort vergessen?
Im Bereich Nachrichten:
Deutsche Bank: Weiter in der Abwärtsspirale!
Experte: Stefan Hofmann, STOCK-WORLD
Tagesausblick für 18.06. ...
HypoVereinsbank onema., (17.06.21)
Experte: HypoVereinsbank onemarkets,
DAX stabil nach Fed-...
CMC Markets, (17.06.21)
Experte: CMC Markets,
DOW DAX weiter seitwärts
Thomas Heydrich, (17.06.21)
Experte: Thomas Heydrich,
Aixtron und Curevac - ..., (17.06.21)
DAX - Belasten schwache ...
Christian Zoller, (17.06.21)
Experte: Christian Zoller,
Euwax-Trends: Impfstoff-...
Cornelia Frey, Börse Stuttgart AG (17.06.21)
Experte: Cornelia Frey, Börse Stuttgart AG
Gold bricht ein, griechische ...
Martin Siegel, STABILITAS FONDS (17.06.21)
Experte: Martin Siegel, STABILITAS FONDS
Die Entwicklung bei den ...
Börse Stuttgart AG, (17.06.21)
Experte: Börse Stuttgart AG,
Europäische ...
Stock-World Redaktion, STOCK-WORLD (17.06.21)
Experte: Stock-World Redaktion, STOCK-WORLD
Bonanza-Gehalte: Fast 54 ...
Björn Junker, (17.06.21)
Experte: Björn Junker,
TUI-Calls mit 121%-Chance ...
Walter Kozubek, (17.06.21)
Experte: Walter Kozubek,
GOLD - Schwäche als ...
Michael Neubauer, Global Investa (17.06.21)
Experte: Michael Neubauer, Global Investa
Niquet's World
Neues vom Portal
Die "Todesgruppe" der Euro 2020 besteht aus Frankreich, Portugal, ...
Letzte Börsen-Meldung
Letzte Börsen-Analyse
Top-Klicks News
Top-Klicks Analysen